Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3
CR20260105APending Publication Date: 2026-06-18AMGEN RESEARCH (MUNICH) GMBH +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CR202600105
- Authority / Receiving Office
- CR · CR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-20
- Filing Date
- 2024-08-20
- Publication Date
- 2026-06-18
Abstract
This disclosure provides methods of treating patients with prostate cancer with an anti-STEAP1 antigen-binding protein, such as xaluritamig, either as monotherapy or in combination with another therapeutic agent.
Need to check novelty before this filing date? Find Prior Art